Overview

Investigation of Optimal Dosage Regimen for HRS9531 Tablets in Healthy Subjects

Status:
NOT_YET_RECRUITING
Trial end date:
2024-11-30
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the effects of different dosage regimen on the pharmacokinetics of HRS9531 tablets in healthy subjects.
Phase:
PHASE1
Details
Lead Sponsor:
Fujian Shengdi Pharmaceutical Co., Ltd.